The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference

Tuesday, January 03, 2012

Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference09:30 EST Tuesday, January 03, 2012TARRYTOWN, N.Y., Jan. 3, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 30th Annual J. P. Morgan Healthcare Conference on Monday, January 9, 2012.  The presentation is scheduled for 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time).  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through February 8, 2012.  Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA? (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com. Contact Information:                               Michael Aberman, M.D.                         Peter DworkinInvestor Relations                                    Corporate Communications914.847.7799                                       914.847.7800michael.aberman@regeneron.com        peter.dworkin@regeneron.com   SOURCE Regeneron Pharmaceuticals, Inc.